关注
Peter Galle
Peter Galle
Professor für Medizin, Mainz University
在 uni-Mainz.de 的电子邮件经过验证
标题
引用次数
引用次数
年份
Sorafenib in advanced hepatocellular carcinoma
JM Llovet, S Ricci, V Mazzaferro, P Hilgard, E Gane, JF Blanc, ...
New England journal of medicine 359 (4), 378-390, 2008
150202008
EASL clinical practice guidelines: management of hepatocellular carcinoma
European Association For The Study Of The Liver
Journal of hepatology 69 (1), 182-236, 2018
67902018
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
RS Finn, S Qin, M Ikeda, PR Galle, M Ducreux, TY Kim, M Kudo, V Breder, ...
New England Journal of Medicine 382 (20), 1894-1905, 2020
49672020
EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma
European Association For The Study Of The Liver
Journal of hepatology 56 (4), 908-943, 2012
47472012
Simplified criteria for the diagnosis of autoimmune hepatitis
EM Hennes, M Zeniya, AJ Czaja, A Parés, GN Dalekos, EL Krawitt, ...
Hepatology 48 (1), 169-176, 2008
22052008
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
M Reig, A Forner, J Rimola, J Ferrer-Fàbrega, M Burrel, Á Garcia-Criado, ...
Journal of hepatology 76 (3), 681-693, 2022
21692022
Cutting edge: TGF-β induces a regulatory phenotype in CD4+ CD25− T cells through Foxp3 induction and down-regulation of Smad7
MC Fantini, C Becker, G Monteleone, F Pallone, PR Galle, MF Neurath
The Journal of Immunology 172 (9), 5149-5153, 2004
16072004
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
J Bridgewater, PR Galle, SA Khan, JM Llovet, JW Park, T Patel, TM Pawlik, ...
Journal of hepatology 60 (6), 1268-1289, 2014
15852014
Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis …
R Atreya, J Mudter, S Finotto, J Müllberg, T Jostock, S Wirtz, M Schütz, ...
Nature medicine 6 (5), 583-588, 2000
15662000
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo …
AX Zhu, YK Kang, CJ Yen, RS Finn, PR Galle, JM Llovet, E Assenat, ...
The lancet oncology 20 (2), 282-296, 2019
15472019
Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo
R Kiesslich, J Burg, M Vieth, J Gnaendiger, M Enders, P Delaney, ...
Gastroenterology 127 (3), 706-713, 2004
12392004
Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells—a mechanism of immune evasion?
S Strand, WJ Hofmann, H Hug, M Müller, G Otto, D Strand, SM Mariani, ...
Nature medicine 2 (12), 1361-1366, 1996
12321996
p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs
M Müller, S Wilder, D Bannasch, D Israeli, K Lehlbach, M Li-Weber, ...
The Journal of experimental medicine 188 (11), 2033-2045, 1998
11651998
Elafibranor, an agonist of the peroxisome proliferator− activated receptor− α and− δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening
V Ratziu, SA Harrison, S Francque, P Bedossa, P Lehert, L Serfaty, ...
Gastroenterology 150 (5), 1147-1159. e5, 2016
11232016
Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis
R Kiesslich, J Fritsch, M Holtmann, HH Koehler, M Stolte, S Kanzler, ...
Gastroenterology 124 (4), 880-888, 2003
11212003
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma
EOF Research, TO Cancer, ...
Journal of hepatology 56 (4), 908-943, 2012
10292012
CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes
I Tiede, G Fritz, S Strand, D Poppe, R Dvorsky, D Strand, HA Lehr, S Wirtz, ...
The Journal of clinical investigation 111 (8), 1133-1145, 2003
10282003
p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias
H Dohner, K Fischer, M Bentz, K Hansen, A Benner, G Cabot, D Diehl, ...
9851995
Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.
PR Galle, WJ Hofmann, H Walczak, H Schaller, G Otto, W Stremmel, ...
The Journal of experimental medicine 182 (5), 1223-1230, 1995
9551995
Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.
M Müller, S Strand, H Hug, EM Heinemann, H Walczak, WJ Hofmann, ...
The Journal of clinical investigation 99 (3), 403-413, 1997
9511997
系统目前无法执行此操作,请稍后再试。
文章 1–20